According to the company, opioid analgesics and nonsteroidal anti-inflammatory drugs will continue to hold leading market status in the acute pain space while new analgesics that will launch over the next decade will not have a significant impact on major market sales or the treatment paradigm for acute pain. In 2011, sales of opioid analgesics and nonsteroidal anti-inflammatory drugs combined, made up more than half of the total major market sales, said Andrea Buurma, a Decision Resources analyst. This trend is expected to continue through 2021.
More Articles on Pain Management:
Physician’s Technology Introduces 5th Generation Device for Joint Pain Relief
Sheikh Zayed Institute for Pediatric Surgical Innovation to Open Children’s Pain Medicine Clinic
Interventional Pain Specialist Joins New England Spine Clinic
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
